Friday, May 17, 2024
The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.
Total income for 9M FY24 stood at Rs.1,651 crore against Rs.1,647 crore YoY
- EBITDA for 9M FY24 at Rs.204.0 crore up by 38.4% YoY
- Net profit for 9M FY24 at Rs.107.2 crore up by 43.5% YoY
- Received CEP Certificate for Losartan Potassium issued by EDQM which will enable higher export to European market
- The Board declared an Interim Dividend of Rs.5/- Share
08th February, 2024, New Delhi:
IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the third quarter and nine months ended December 31, 2023.
Consolidated Q3 & 9M FY24 Financial Highlights
(Rs. in Crore)|
Particulars |
Q3 FY24 |
Q3 FY23 |
% YoY |
9M FY24 |
9M FY23 |
% YoY |
|
Total Income |
528.8 |
530.1 |
-0.2% |
1651.4 |
1,646.8 |
0.3% |
|
EBITDA |
52.9 |
49.7 |
6.4% |
204.0 |
147.6 |
38.2% |
|
EBITDA Margin (%) |
10.0% |
9.4% |
60 bps |
12.3% |
8.9% |
340 bps |
|
PAT |
23.2 |
24.2 |
-4.1% |
107.2 |
74.7 |
43.5% |
|
PAT Margin (%) |
4.4% |
4.6% |
-20 bps |
6.5% |
4.5% |
200 bps |
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Despite sectoral headwinds, the Company has shown resilience in its financial performance during nine months period. The company’s EBITDA margin has improved led by declining input cost. We recently received CEP certificate approval for Losartan Potassium by EDQM providing us an opportunity to further expand our exports into the regulated markets. We are continuously focusing on improving operational efficiencies further through backward integration.”
About IOL Chemicals and Pharmaceuticals Limited (IOLCP)
Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like Pain Management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.
The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.
The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.
The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.
IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.
.jpg)
